Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board
07:30am, Thursday, 17'th Jun 2021
NEW YORK, June 17, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of
Is Mind Medicine a Buy?
06:11am, Thursday, 17'th Jun 2021
It offers a great way to tap into the psychedelics market -- but is it too risky of an investment right now?
4 Penny Stocks to Watch Following the Fed Meeting and Powell's Remarks
05:14pm, Wednesday, 16'th Jun 2021
Which penny stocks are investors watching following Powell's remarks and the Fed meeting? The post 4 Penny Stocks to Watch Following the Fed Meeting and Powell's Remarks appeared first on Penny Stocks
Could Mind Medicine Be a Millionaire-Maker Stock?
09:55am, Wednesday, 16'th Jun 2021
Yes, but with the chance of great reward comes substantial risk.
MNMD Stock Price Increases Over 3% Pre-Market: Why It Happened
09:06am, Wednesday, 16'th Jun 2021
The stock price of Mind Medicine (MindMed) Inc (NASDAQ: MNMD) increased by over 3% pre-market. This is why it happened.
3 Psychedelics Stocks Getting High Thanks to the Newly Launched PSY ETF
05:22pm, Tuesday, 15'th Jun 2021
These psychedelic stocks have compelling product pipelines and have built up a great head of steam in the past month thanks to the PSY ETF. The post 3 Psychedelics Stocks Getting High Thanks to the Ne
Mind Medicine Stock Might Still Be Worth the Risk Here
07:27am, Friday, 11'th Jun 2021
While MNMD stock is incredibly speculative due to uncertainties of psychedelic therapeutics, the need may transcend the risks. The post Mind Medicine Stock Might Still Be Worth the Risk Here appeared
Why Shares of MindMed Dropped 13% in May
03:59pm, Wednesday, 09'th Jun 2021
Froth from its uplisting is having an impact.
J.R. Rahn Steps Down As MindMed CEO
09:06am, Wednesday, 09'th Jun 2021
Mind Medicine Inc. (NASDAQ:MNMD), more commonly known as MindMed, has announced co-founder and chief executive J.R. Rahn is stepping down from his leadership role, effective immediately.
MindMed Announces Chief Executive Officer Transition
07:17am, Wednesday, 09'th Jun 2021
NEW YORK, June 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of
Stockwatch: MindMed Is Added To The MSCI Small Cap Canada Index
01:20pm, Sunday, 30'th May 2021
Mind Medicine is a leading psychedelic pharmaceutical company and the first to be publicly listed. On Thursday, it became the first NEO-listed company to be included in an MSCI Index.
NEO Exchange Announces Eligibility In MSCI Indexes
08:30am, Friday, 28'th May 2021
TORONTO--(BUSINESS WIRE)-- #MSCI--MSCI Inc. now recognizes NEO as an eligible market for inclusion in MSCI Indexes under the MSCI Global Investable Market Indexes Methodology.
MindMed announces shareholder Meeting Results
06:30pm, Thursday, 27'th May 2021
NEW YORK, May 27, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that each of the resolutions put before
Mind Medicine Stock Is Not a Trip To Take Just Yet
05:01am, Thursday, 27'th May 2021
Psychedelic drugs may eventually be a big market. However, investors in MNMD stock may be getting in a little too early.
MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing
07:30am, Wednesday, 26'th May 2021
NEW YORK, May 26, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today the publication of the first pharmacogenetic data o
